FDA Approves OZEMPIC — Novo Nordisk Pharmaceutical Industries, LP

# FDA Approves Novo Nordisk's Ozempic for Type 2 Diabetes Treatment Novo Nordisk Pharmaceutical Industries, LP received FDA approval for Ozempic (semaglutide), a once-weekly subcutaneous injection for type 2 diabetes, positioning the company to capture significant market share in the competitive GLP-1 receptor agonist class. The approval is expected to drive substantial revenue growth for Novo Nordisk and intensify competition in the diabetes treatment market against established players like Eli Lilly and Amgen.